SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, announced today that long-term follow-up data from its Phase 2 clinical trial of FavId(R) following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin’s lymphoma (NHL) will be presented at the American Society of Hematology (ASH) Annual Meeting in Atlanta. The data will be presented by co-primary investigator Omer Koc, M.D., Staff Physician, Hematology/Oncology, at the Cleveland Clinic Foundation, during an oral presentation on Tuesday, December 13, 2005 at 8:15 a.m. EST at the Georgia World Congress Center.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )
In addition, Favrille will host a post-ASH data briefing at Le Parker Meridien in New York City on Wednesday, December 14, 2005 at 4:30 p.m. EST to discuss the Phase 2 data and its implications for the Company’s ongoing Phase 3 clinical trial. Favrille’s management team will be joined by Paul Hamlin, M.D., from the Memorial Sloan-Kettering Cancer Center in New York, and John Timmerman, M.D., from the Division of Hematology & Oncology at the University of California, Los Angeles. To RSVP for the post-ASH data briefing, please contact Katie Compa at (212) 331-7813 or kcompa@weisscommpartners.com. A live webcast of the event can be accessed at www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until January 14, 2006.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.
CONTACT: Tamara A. Seymour, CFO and Vice President, Finance &Administration, +1-858-526-8035, tseymour@favrille.com, or Pete De Spain,Associate Director, Investor Relations & Corporate Communications,+1-858-526-2426, pdespain@favrille.com, both of Favrille, Inc.
Web site: http://www.favrille.com/
